(VIANEWS) - XOMA Corporation (XOMA), Syneos Health (SYNH), Ares Commercial Real Estate Corporation (ACRE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. XOMA Corporation (XOMA)
61.2% sales growth and 11.52% return on equity
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific.
XOMA Corporation's sales growth this year is anticipated to be 27.2% and a negative 45.7% for next year.
Year-on-year quarterly revenue growth grew by 68.8%, now sitting on 29.8M for the twelve trailing months.
Volume
Today's last reported volume for XOMA Corporation is 20751 which is 0.85% above its average volume of 20576.
XOMA Corporation's sales growth for the next quarter is 61.2%. The company's growth estimates for the current quarter and the next is 72% and 61.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.52%.
Volatility
XOMA Corporation's last day, last week, and last month's current intraday variation average was 3.74%, 4.81%, and 4.62%, respectively.
XOMA Corporation's highest amplitude of average volatility was 10.40% (day), 9.58% (last week), and 8.66% (last month), respectively.
XOMA Corporation's Stock Yearly Top and Bottom Value
XOMA Corporation's stock is valued at $23.32 at 05:22 EST, way under its 52-week high of $46.32 and way higher than its 52-week low of $19.40.
XOMA Corporation's Moving Average
XOMA Corporation's worth is below its 50-day moving average of $23.41 and way below its 200-day moving average of $29.57.2. Syneos Health (SYNH)
17% sales growth and 7.82% return on equity
Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Syneos Health's sales growth this year is expected to be 18.9% and 9.4% for next year.
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 4.98B for the twelve trailing months.
Volume
Today's last reported volume for Syneos Health is 641584 which is 8.75% above its average volume of 589914.
Syneos Health's sales growth for the next quarter is 17%. The company's growth estimates for the ongoing quarter and the next is 29.7% and 34.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.82%.
Volatility
Syneos Health's last day, last week, and last month's current intraday variation average was 0.85%, 1.48%, and 1.76%, respectively.
Syneos Health's highest amplitude of average volatility was 4.14% (day), 3.66% (last week), and 3.74% (last month), respectively.
Syneos Health's Stock Yearly Top and Bottom Value
Syneos Health's stock is valued at $100.08 at 05:22 EST, below its 52-week high of $104.18 and way above its 52-week low of $64.18.
Syneos Health's Moving Average
Syneos Health's value is above its 50-day moving average of $94.85 and way above its 200-day moving average of $87.92.3. Ares Commercial Real Estate Corporation (ACRE)
16.1% sales growth and 10.11% return on equity
Ares Commercial Real Estate Corporation, a specialty finance company, originates and invests in commercial real estate (CRE) loans and related investments in the United States.
Ares Commercial Real Estate Corporation's sales growth this year is expected to be 18% and 11.4% for next year.
Year-on-year quarterly revenue growth declined by 11.2%, now sitting on 94.13M for the twelve trailing months.
Volume
Today's last reported volume for Ares Commercial Real Estate Corporation is 837820 which is 134.45% above its average volume of 357354.
Ares Commercial Real Estate Corporation's sales growth for the next quarter is 16.1%. The company's growth estimates for the ongoing quarter and the next is a negative 9.8% and negative -10%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.11%.
Volatility
Ares Commercial Real Estate Corporation's last day, last week, and last month's current intraday variation average was 2.30%, 1.20%, and 1.19%, respectively.
Ares Commercial Real Estate Corporation's highest amplitude of average volatility was 3.23% (day), 1.98% (last week), and 2.14% (last month), respectively.
Ares Commercial Real Estate Corporation's Stock Yearly Top and Bottom Value
Ares Commercial Real Estate Corporation's stock is valued at $14.36 at 05:22 EST, way below its 52-week high of $16.98 and way higher than its 52-week low of $11.16.
Ares Commercial Real Estate Corporation's Moving Average
Ares Commercial Real Estate Corporation's worth is below its 50-day moving average of $15.47 and under its 200-day moving average of $15.10.4. SVB Financial Group (SIVB)
9.8% sales growth and 18.59% return on equity
SVB Financial Group's sales growth this year is expected to be 38% and 2.1% for next year.
Year-on-year quarterly revenue growth grew by 37%, now sitting on 5.59B for the twelve trailing months.
Volume
Today's last reported volume for SVB Financial Group is 48518 which is 85.91% below its average volume of 344541.
SVB Financial Group's sales growth for the next quarter is 9.8%. The company's growth estimates for the ongoing quarter and the next is a negative 40.3% and negative -11.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.59%.
Volatility
SVB Financial Group's last day, last week, and last month's current intraday variation average was 0.60%, 2.59%, and 1.98%, respectively.
SVB Financial Group's highest amplitude of average volatility was 1.22% (day), 2.72% (last week), and 3.21% (last month), respectively.
SVB Financial Group's Stock Yearly Top and Bottom Value
SVB Financial Group's stock is valued at $676.72 at 05:22 EST, way under its 52-week high of $763.22 and way above its 52-week low of $349.48.